

Brussels Statement

Brussels statement on breast cancer 2000

Introduction

The second European Breast cancer conference reached a consensus on several key issues during the closing plenary session on the 30th September 2000 in Brussels. Clinicians, scientists, and health care consumers representing 3150 participants used a computerised voting system in plenary session to formulate the *Brussels Statement*.

This document sets the agenda for the future activities of the three major groups involved in breast cancer research, treatment, prevention and advocacy :

- The Breast Cancer Group of the European Organization for Research and Treatment in Cancer (EORTC-BCG)
- The European Society of Mastology (EUSOMA)
- Europa Donna, the European Breast Cancer Coalition

It is hoped that the objectives outlined in this document will stimulate much-needed change in the field of breast cancer. EORTC-BCG, EUSOMA together with the breast cancer advocacy activities of EUROPA DONNA, will work towards these goals by lobbying European Governments and the European Commission and by mobilising health-service providers, the scientific community and the health - care industry. These measures called for by EBCC-2 delegates will be assessed and reviewed at EBCC-3 to be held in Barcelona in March 2002.

Breast cancer is the commonest cancer and the most frequent cause of cancer death in women throughout Europe. Because of its importance and its potential for successful treatment, breast cancer deserves special attention and effort.

Chairman

Professor M. Piccart
Institut Bordet, Belgium

Conference Secretariat

FECS Conference Unit, Avenue E. Mounier 83, B-1200 Brussels, Belgium
Tel.: +32 (2) 775 02 01/ Fax: +32 (2) 775 02 00/e-mail: EBCC-2@fece.be



Brussels Statement

The Brussels conference makes the following statements:

Breast cancer should be managed in multidisciplinary clinics

Following the Florence Statement which established that all women should have access to fully equipped, dedicated breast units, the three Societies have produced European Guidelines defining the requirements for such units. These European guidelines stress the importance of multidisciplinary (ie the collaboration between surgeons, radiologists, clinicians, pathologists, etc...) and multiprofessionalism (ie the collaboration between doctors, nurses, psychologists, social workers, etc..).

The Conference demands that national governments establish and accredit breast units in their countries in accordance with the Guidelines and ensure that breast cancer diagnosis and care are carried out in those units.

All breast units should develop quality assurance programmes entering their data onto a common European database. The Conference pleads for all the breast units to collect data on incidence and mortality and to pool them in a common European database.

Breast cancer screening

The conference acknowledges the important contribution made by mammographic screening to decreasing mortality and improving breast cancer care. All women should be offered full information about the benefits and risks of mammographic screening.

All European women between the age of 50 and 75 should be offered quality-assured mammographic breast screening free at the point of delivery. Programmes should not be provided without adequate provision for assessment and treatment of screen-detected abnormalities.

Chairman

Professor M. Piccart
Institut Bordet, Belgium

Conference Secretariat

FECS Conference Unit, Avenue E. Mounier 83, B-1200 Brussels, Belgium
Tel.: +32 (2) 775 02 01/ Fax: +32 (2) 775 02 00/e-mail: EBCC-2@fecs.be



Brussels Statement

Quality assurance in breast cancer research

The Conference wishes to stress the importance of quality assurance procedures as an integral part of the conduct of studies for all involved disciplines. It invites health service providers and research funding agencies to consider the additional cost for quality assurance procedures as an investment to obtain better outcomes.

Researchers and clinical investigators should recognise the ethical and scientific necessity of always including quality assurance procedures in their study protocols.

Risk assessment

The Conference wishes to bring to everyone's attention the increasing potentials offered by new methods to assess breast cancer risk for an individual woman and encourages researchers to identify a standardised risk-assessment methodology suitable for European women. This will facilitate research in preventive measures such as mammography and innovative imaging modalities, lifestyle modifications, chemoprevention, and prophylactic surgery.

In addressing the issue of genetic testing the Conference agreed that not all women with a family history are at high risk and necessarily need or want a genetic test.

Genetic testing should be provided only after receiving appropriate specialist counselling.

The Conference expresses the opinion that genetic testing should not be encouraged in the absence of protective legislation against socio-economic discrimination.

Treatment tailoring

The Conference welcomes the progress made in tailoring treatment programmes to individual patients and acknowledges the fact that a great contribution to this progress comes from translational research (ie those studies which result from the interaction between laboratory and clinical research).

The Conference wishes to assist in the coming years to a great development of translational research in breast cancer by means of well-funded research projects on frozen tumour specimens for which free circulation among different countries should also be ensured. Legislators on data protection are asked to facilitate this scientific evolution by recognising the importance of these studies.

Informed consented collection of frozen tumour specimens should be obtained from all breast cancer patients as a routine procedure.

Chairman

Conference Secretariat



Professor M. Piccart
Institut Bordet, Belgium

FECS Conference Unit, Avenue E. Mounier 83, B-1200 Brussels, Belgium
Tel.: +32 (2) 775 02 01/ Fax: +32 (2) 775 02 00/e-mail: EBCC-2@fece.be

Brussels Statement

Participation in clinical trials

Randomized clinical trials represent the most effective way of evaluating new therapies but also offer optimal treatment opportunities. Positive steps should be taken to minimise obstacles to the participation both for patients and clinicians.

Press, broadcasting media and internet providers are invited to increase awareness of the importance of participation in clinical trials as the most important contribution to the progress of medicine and the best option for maximum quality care. Health authorities and research agencies should give adequate support to national and international data centres conducting clinical trials in breast cancer.

Martine Piccart
Conference Chair

Gloria Freilich
Conference Co-Chair

Luigi Cataliotti
President EUSOMA

Mary Buchanan
President Europa Donna

Jacek Jassem
President EORTC-Breast Group

Chairman

Conference Secretariat



Professor M. Piccart
Institut Bordet, Belgium

FECS Conference Unit, Avenue E. Mounier 83, B-1200 Brussels, Belgium
Tel.: +32 (2) 775 02 01/ Fax: +32 (2) 775 02 00/e-mail: EBCC-2@fecs.be